Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

1
results for

"Pei-Wu Zhu"

Article category

Keywords

Publication year

"Pei-Wu Zhu"

Original Article

Steatotic liver disease

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients
Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng
Clin Mol Hepatol 2022;28(2):183-195.
Published online November 28, 2021
DOI: https://doi.org/10.3350/cmh.2021.0301
Background/Aims
Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL) gene in human, has been implicated in the pathogenesis of metabolic dysfunctions. However, the impact of variants in KL on NAFLD risk remains poorly understood. The aim of this study was to investigate the impact of KL rs495392 C>A polymorphism on the histological severity of NAFLD.
Methods
We evaluated the impact of the KL rs495392 polymorphism on liver histology in 531 Chinese with NAFLD and replicated that in the population-based Rotterdam Study cohort. The interactions between the rs495392, vitamin D, and patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 polymorphism were also analyzed.
Result
s: Carriage of the rs495392 A allele had a protective effect on steatosis severity (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.42–0.89; P=0.010) in Chinese patients. After adjustment for potential confounders, the A allele remained significant with a protective effect (OR, 0.66; 95% CI, 0.45–0.98; P=0.040). The effect on hepatic steatosis was confirmed in the Rotterdam Study cohort. Additional analysis showed the association between serum vitamin D levels and NAFLD specifically in rs495392 A allele carriers, but not in non-carriers. Moreover, we found that the rs495392 A allele attenuated the detrimental impact of PNPLA3 rs738409 G allele on the risk of severe hepatic steatosis.
Conclusions
The KL rs495392 polymorphism has a protective effect against hepatic steatosis in patients with NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury
    Ehab E. Sharata, Mina Ezzat Attya, Marwa M. Khalaf, Remon Roshdy Rofaeil, Ramadan A. M. Hemeida, Amira M. Abo-Youssef
    Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(2): 2097.     CrossRef
  • Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation
    Sin Man Lam, Zehua Wang, Jin-Wen Song, Yue Shi, Wen-Yue Liu, Lin-Yu Wan, Kaibo Duan, Gek Huey Chua, Yingjuan Zhou, Guibin Wang, Xiahe Huang, Yingchun Wang, Fu-Sheng Wang, Ming-Hua Zheng, Guanghou Shui
    Cell Metabolism.2025; 37(1): 69.     CrossRef
  • Levomilnacipran alleviates cyclophosphamide-induced hepatic dysfunction in male Wistar albino rats; emerging role of α-Klotho/TLR4/p38-MAPK/NF-κB p65 and caspase-3-driven apoptosis trajectories
    Ehab E. Sharata, Mina Ezzat Attya, Marwa M. Khalaf, Remon Roshdy Rofaeil, Amira M. Abo-Youssef, Ramadan A.M. Hemeida
    International Immunopharmacology.2025; 152: 114384.     CrossRef
  • Apremilast attenuates methotrexate-induced hepatic injury in rats; insights into TLR4/NF-κB/P38 MAPK/caspase-3 and α-klotho/Nrf2/HO-1 signaling network interplay
    Reham H. Mohyeldin, Ehab E. Sharata, Mahmoud Abdelnaser, Ayman M. Ibrahim, Mina Ezzat Attya, Al Shaimaa Mahmoud Kotb, Ahmed S.Aboalela, Remon Roshdy Rofaeil
    Toxicology and Applied Pharmacology.2025; 505: 117596.     CrossRef
  • Buspirone combats cyclophosphamide-provoked hepatotoxicity in rats via activation of AMPK/Nrf2/HO-1 and suppression of NF-κB p65 /NLRP3 inflammasome pathways
    Marwa M. Khalaf, Ehab E. Sharata, Waleed A. I. Khallaf, Mina Ezzat Attya, Amira M. Abo-Youssef, Ramadan A. M. Hemeida, Remon Roshdy Rofaeil
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub]     CrossRef
  • The relationship of serum klotho levels and triglyceride glucose index-related indicators
    Yaoyao Zhou, Yaqi Wang, Fangli Li, Yiming Shi, Taotao Wu, Yingshuai Li
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
    Jacob Nysather, Eda Kaya, Paul Manka, Prakash Gudsoorkar, Wing-Kin Syn
    Advances in Kidney Disease and Health.2023; 30(4): 315.     CrossRef
  • Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases
    Yuanbin Liu, Mingkai Chen
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102854.     CrossRef
  • Advances in genetic variation in metabolism-related fatty liver disease
    Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Klotho Levels and Their Relationship with Inflammation and Survival among Alcoholic Patients
    Candelaria Martín-González, Elisa Espelosín-Ortega, Pedro Abreu-González, Camino Fernández-Rodríguez, Víctor Eugenio Vera-Delgado, Lourdes González-Navarrete, Alen García-Rodríguez, Antonio Martínez Riera, Emilio González-Reimers
    Biomolecules.2022; 12(8): 1151.     CrossRef
  • CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice
    Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren
    International Journal of Molecular Sciences.2022; 23(24): 15931.     CrossRef
  • 9,860 View
  • 232 Download
  • 12 Web of Science
  • Crossref